BNTCNasdaqPharmaceutical PreparationsFiscal year ends June 30

Benitec Biopharma Inc.

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 14, 2026

$8.36+0.25 (+3.08%)

Close on Oct 19, 2026

Market cap: $413.29M
P/E (TTM): –
Dividend yield: –

Benitec Biopharma Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-06-30	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30	FY 2020 2020-06-30	FY 2019 2019-06-30
Revenue	–	–	0	0.08	0.07	0.06	0.10	12
Research & Development	23	18	16	13	11	7.02	3.00	4.57
General & Administrative	28	23	6.99	6.38	6.65	6.51	5.57	4.61
Operating Expenses	51	42	22	19	18	14	8.38	9.62
Operating Income	-51	-42	-22	-19	-18	-14	-8.28	2.58
Other Non-Operating Income	5.65	3.85	0.74	-0.48	-0.35	-0.29	0.01	0.03
Gain (Loss) on Sale of Assets	0	–	–	–	–	–	0.00	-0.01
Income Tax Expense	0	–	–	–	–	–	–	–
Net Income	-46	-38	-22	-20	-18	-14	-8.27	2.61
Net Income to Common	-46	-38	-22	-20	–	–	–	–
EPS (Basic)(per share)	-0.98	-1.05	-1.22	-3.14	-8.42	-0.72	-1.80	0.68
EPS (Diluted)(per share)	-0.98	-1.05	-1.22	-3.14	-8.42	-0.72	-1.80	0.68
Shares Outstanding (Basic, Weighted)(shares)	47	36	18	6.24	2.16	19	4.60	3.86
Shares Outstanding (Diluted, Weighted)(shares)	47	36	18	6.24	2.16	19	4.60	3.86
EBITDA	-51	-42	-22	-19	-18	-13	-8.09	2.74

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2026: -33.2%

Financial strength

Current ratio: 34.00
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 3367.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 2.33
Dividend yield: –